Neuren Pharmaceuticals Limited has released a press release.
Trofinetide US patent protections extended to March 2041
Earlier from Neuren Pharmaceuticals
- Growing royalty anchors Neuren first ever dividend program
- European Commission grants marketing authorisation for DAYBU
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union